Creso Pharma’s Board expects that upcoming regulatory changes in the North American psychedelic and recreational cannabis sectors will facilitate a multitude of strategic growth opportunities in the near term for CPH.
The legislative changes include regulation aimed at legalising, taxing and regulating recreational cannabis, as well as to legalise the use and possession of psilocybin and other psychedelic compounds in California. CPH is strategically positioned to leverage its subsidiaries, Mernova and Halucenex, to capitalise on these developments.
CPH and RLH have both mutually agreed to terminate their proposed merger agreement, allowing CPH to retain its ASX listing and pursue a listing on the NASDAQ Exchange. CPH believes this to be in the best interest of its shareholders.
To expedite the dual listing process, CPH have secured an agreement with EAS Advisors LLC, a New-York based corporate advisory firm. This process is expected to provide access to deeper pools of capital as well as access to North American investors, providing opportunities to grow CPH’s verticals and provide value for shareholders.
CPH and RLH will continue to collaborate and are committed to an ongoing relationship. Bruce Linton will also remain as a strategic advisor and major stakeholder in CPH.
